Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.
Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, Suresh R, Ademuyiwa FO, Rigden C, Rearden TP, Clifton K, Weilbaecher K, Frith A, Tandra PK, Summa T, Haas B, Thomas S, Hernandez-Aya LF, Peterson LL, Wang X, Luo SJ, Zhou K, Du P, Jia S, King BL, Krishnamurthy J, Ma CX. Davis AA, et al. Clin Cancer Res. 2023 May 1;29(9):1719-1729. doi: 10.1158/1078-0432.CCR-22-2177. Clin Cancer Res. 2023. PMID: 36693175 Free PMC article.
The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
Jacob S, Davis AA, Gerratana L, Velimirovic M, Shah AN, Wehbe F, Katam N, Zhang Q, Flaum L, Siziopikou KP, Platanias LC, Gradishar WJ, Behdad A, Bardia A, Cristofanilli M. Jacob S, et al. Among authors: davis aa. Clin Cancer Res. 2021 Mar 1;27(5):1361-1370. doi: 10.1158/1078-0432.CCR-20-1566. Epub 2020 Dec 15. Clin Cancer Res. 2021. PMID: 33323406
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China.
Liu X, Davis AA, Xie F, Gui X, Chen Y, Zhang Q, Gerratana L, Zhang Y, Shah AN, Behdad A, Wehbe F, Huang Y, Yu J, Du P, Jia S, Li H, Cristofanilli M. Liu X, et al. Among authors: davis aa. Breast Cancer Res Treat. 2021 Nov;190(2):213-226. doi: 10.1007/s10549-021-06370-w. Epub 2021 Sep 1. Breast Cancer Res Treat. 2021. PMID: 34471951 Free PMC article.
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
Davis AA, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Hensing WL, Bucheit L, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Gradishar WJ, Behdad A, Ma CX, Bardia A, Cristofanilli M. Davis AA, et al. EBioMedicine. 2022 Dec;86:104316. doi: 10.1016/j.ebiom.2022.104316. Epub 2022 Nov 1. EBioMedicine. 2022. PMID: 36332363 Free PMC article.
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.
Hensing WL, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Behdad A, Ma CX, Bardia A, Cristofanilli M, Davis AA. Hensing WL, et al. Among authors: davis aa. Clin Cancer Res. 2023 Aug 15;29(16):3092-3100. doi: 10.1158/1078-0432.CCR-22-3785. Clin Cancer Res. 2023. PMID: 37265453
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
Gerratana L, Davis AA, Velimirovic M, Clifton K, Hensing WL, Shah AN, Dai CS, Reduzzi C, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Puglisi F, Ma CX, Bardia A, Cristofanilli M. Gerratana L, et al. Among authors: davis aa. Breast Cancer Res. 2023 Oct 2;25(1):112. doi: 10.1186/s13058-023-01718-0. Breast Cancer Res. 2023. PMID: 37784176 Free PMC article.
Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells and DNA.
Zhang Q, Cai Z, Gerratana L, Davis AA, D'Amico P, Chawla A, Jacob S, Zhang Y, Jiao J, Qin W, Reduzzi C, Flaum L, Shah A, Gradishar WJ. Zhang Q, et al. Among authors: davis aa. Clin Cancer Res. 2024 Aug 15;30(16):3470-3480. doi: 10.1158/1078-0432.CCR-24-0535. Clin Cancer Res. 2024. PMID: 38829582
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling.
Gerratana L, Davis AA, Foffano L, Reduzzi C, Rossi T, Medford A, Clifton K, Shah AN, Bucheit L, Velimirovic M, Bandini S, Dai CS, Wehbe F, Gradishar WJ, Behdad A, Ulivi P, Ma CX, Puglisi F, Bardia A, Cristofanilli M. Gerratana L, et al. Among authors: davis aa. Cancer Lett. 2025 Jan 28;609:217325. doi: 10.1016/j.canlet.2024.217325. Epub 2024 Nov 20. Cancer Lett. 2025. PMID: 39577685
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer.
Shah AN, Carroll KJ, Gerratana L, Lin C, Davis AA, Zhang Q, Jacob S, Finkelman B, Zhang Y, Qiang W, D'Amico P, Reduzzi C, Gradishar WJ, Behdad A, Cristofanilli M. Shah AN, et al. Among authors: davis aa. Breast Cancer Res Treat. 2021 Jun;187(2):397-405. doi: 10.1007/s10549-021-06236-1. Epub 2021 Jun 2. Breast Cancer Res Treat. 2021. PMID: 34076801
178 results